Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906770 | 0.94 | PTPN1 (0.47) | CNR1EIF4E | |
| SCHEMBL4805155 | 0.87 | CNR1 (0.47) | CNR1 | |
| SCHEMBL3889534 | 0.81 | CNR1 (0.50) | CNR1EIF4E | |
| SCHEMBL3114608 | 0.80 | DPP4 (0.44) | — | |
| SCHEMBL4807852 | 0.79 | CNR1 (0.48) | CNR1EIF4E | |
| SCHEMBL3880353 | 0.76 | CNR1 (0.46) | CNR1EIF4E | |
| SCHEMBL4511779 | 0.76 | MAPT (0.48) | CNR1 | |
| SCHEMBL3114685 | 0.76 | CRHR1 (0.38) | CNR1 | |
| SCHEMBL4910547 | 0.76 | DPP4 (0.45) | CNR1 | |
| SCHEMBL4912775 | 0.74 | CNR1 (0.46) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345059-B2 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2008-03-18 | — | — | US | disclosed |
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | SANOFI-AVENTIS (FR) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189664-A1 | Diphenylpyridine derivatives, preparation and therapeutic application thereof | CNR1, HDAC10, AKR1B10 | CNR1 1/4885EIF4E 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.